CD93 has recently been recognized as a key receptor that interacts with IL-17D, and its involvement in regulating angiogenesis, inflammation, and tumor progression has been well documented (Samstein et al., 2019; Szczesny-Malysiak et al., 2020; Campagna et al., 2021). The gene discussed is IL17D; the disease is neoplasm.